Literature DB >> 21375774

Radiation recall pneumonitis induced by chemotherapy after thoracic radiotherapy for lung cancer.

Xiao Ding1, Wei Ji, Junling Li, Xiangru Zhang, Luhua Wang.   

Abstract

BACKGROUND: Radiation recall pneumonitis (RRP) describes a rare reaction in previously irradiated area of pulmonary tissue after application of triggering agents. RRP remains loosely characterized and poorly understood since it has so far only been depicted in 8 cases in the literature. The objective of the study is to disclose the general characteristics of RRP induced by chemotherapy after thoracic irradiation for lung cancer, and to draw attention to the potential toxicity even after a long time interval from the previous irradiation.
METHODS: Medical records were reviewed. RRP induced by chemotherapy was diagnosed by the history of chemotherapy after radiotherapy, clinical presentation and radiographic abnormalities including ground-glass opacity, attenuation, or consolidation changes within the radiation field, plus that radiographic examination of the thorax before showed no radiation pneumonitis. RRP was graded according to Common Terminology Criteria for Adverse Events version 3.0. The characteristics of the 12 RRP cases were analyzed.
RESULTS: Twelve patients were diagnosed of RRP, of who 8 received taxanes. The median time interval between end of radiotherapy and RRP, between end of radiotherapy and beginning of chemotherapy, and between beginning of chemotherapy and RRP was 95 days, 42 days and 47 days, respectively. Marked symptomatic and radiographic improvement was observed in the 12 patients after withdrawal of chemotherapy and application of systemic corticosteroids. Seven patients were rechallenged with chemotherapy, of whom four with the same kind of agents, and showed no recurrence with steroid cover.
CONCLUSIONS: Doctors should pay attention to RRP even after a long time from the previous radiotherapy or after several cycles of consolidation chemotherapy. Taxanes are likely to be associated with radiation recall more frequently. Withdrawal of causative agent and application of steroids are the treatment of choice. Patients may be rechallenged safely with steroid cover and careful observation, which needs to be validated.

Entities:  

Mesh:

Year:  2011        PMID: 21375774      PMCID: PMC3063220          DOI: 10.1186/1748-717X-6-24

Source DB:  PubMed          Journal:  Radiat Oncol        ISSN: 1748-717X            Impact factor:   3.481


  30 in total

1.  Radiation recall dermatitis may represent the Koebner phenomenon.

Authors:  Ross Camidge; Allan Price
Journal:  J Clin Oncol       Date:  2002-10-01       Impact factor: 44.544

2.  Tamoxifen-induced radiation recall dermatitis.

Authors:  Eric A Singer; Robert D Warren; Marie F Pennanen; Brian T Collins; Daniel F Hayes
Journal:  Breast J       Date:  2004 Mar-Apr       Impact factor: 2.431

Review 3.  Radiation recall with oxaliplatin: report of a case and a review of the literature.

Authors:  R T Chan; G K Au; J W Ho; K W Chu
Journal:  Clin Oncol (R Coll Radiol)       Date:  2001       Impact factor: 4.126

4.  Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumors.

Authors:  D Castellano; R Hitt; E Ciruelos; H Cortés-Funes; R Colomer
Journal:  Ann Oncol       Date:  2003-05       Impact factor: 32.976

Review 5.  Characterizing the phenomenon of radiation recall dermatitis.

Authors:  R Camidge; A Price
Journal:  Radiother Oncol       Date:  2001-06       Impact factor: 6.280

6.  Radiation recall--another call with tamoxifen.

Authors:  A Boström; G Sjölin-Forsberg; N Wilking; J Bergh
Journal:  Acta Oncol       Date:  1999       Impact factor: 4.089

Review 7.  Gemcitabine-induced radiation recall.

Authors:  Melenda D Jeter; Pasi A Jänne; Sarah Brooks; Harold J Burstein; Patrick Wen; Charles S Fuchs; Jay S Loeffler; Phillip M Devlin; Ravi Salgia
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-06-01       Impact factor: 7.038

Review 8.  Gemcitabine-related radiation recall preferentially involves internal tissue and organs.

Authors:  Philip A Friedlander; Roopa Bansal; Lawrence Schwartz; Raquel Wagman; Jerome Posner; Nancy Kemeny
Journal:  Cancer       Date:  2004-05-01       Impact factor: 6.860

9.  "Recall" pneumonitis: adriamycin potentiation of radiation pneumonitis in two children.

Authors:  L D Ma; G A Taylor; M D Wharam; J M Wiley
Journal:  Radiology       Date:  1993-05       Impact factor: 11.105

10.  Photo recall effect in association with cefazolin.

Authors:  Luis A Garza; Elisa K Yoo; Jacqueline M Junkins-Hopkins; Abby S VanVoorhees
Journal:  Cutis       Date:  2004-01
View more
  23 in total

1.  Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers.

Authors:  Tomomi W Nobashi; Yuko Nishimoto; Yujiro Kawata; Hidetaka Yutani; Masaki Nakamura; Yuichi Tsuji; Atsushi Yoshida; Akihiko Sugimoto; Takayuki Yamamoto; Israt S Alam; Satoshi Noma
Journal:  Br J Radiol       Date:  2020-08-12       Impact factor: 3.039

2.  Radiation recall pneumonitis induced by nivolumab in a patient with renal cell carcinoma.

Authors:  Kenji Nakamura; Kazutoshi Okubo; Takeshi Takahashi; Kenji Mitsumori; Takashi Ishigaki; Hiroyuki Ohnishi
Journal:  IJU Case Rep       Date:  2018-11-26

3.  Detection and early phase assessment of radiation-induced lung injury in mice using micro-CT.

Authors:  Shigeyoshi Saito; Kenya Murase
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

4.  Radiation recall reaction causing cardiotoxicity.

Authors:  Sofia Carolina Masri; Andrew James Misselt; Arkadiusz Dudek; Suma H Konety
Journal:  J Cardiovasc Magn Reson       Date:  2014-04-22       Impact factor: 5.364

5.  Optimal beam arrangement for pulmonary ventilation image-guided intensity-modulated radiotherapy for lung cancer.

Authors:  Ruihao Wang; Shuxu Zhang; Hui Yu; Shengqu Lin; Guoqian Zhang; Rijie Tang; Bin Qi
Journal:  Radiat Oncol       Date:  2014-08-16       Impact factor: 3.481

6.  Polydatin alleviated radiation-induced lung injury through activation of Sirt3 and inhibition of epithelial-mesenchymal transition.

Authors:  Kun Cao; Xiao Lei; Hu Liu; Hainan Zhao; Jiaming Guo; Yuanyuan Chen; Yang Xu; Ying Cheng; Cong Liu; Jianguo Cui; Bailong Li; Jianming Cai; Fu Gao; Yanyong Yang
Journal:  J Cell Mol Med       Date:  2017-06-13       Impact factor: 5.310

7.  Radiation recall dermatitis triggered by sorafenib after radiation therapy for hepatocellular carcinoma.

Authors:  Gwi Eon Kim; Hee-Sung Song; Ki Jung Ahn; Young Suk Kim
Journal:  Radiat Oncol J       Date:  2017-09-29

8.  Pemetrexed-Induced Interstitial Pneumonitis: A Case Study and Literature Review.

Authors:  Michael J Waters; Shawgi Sukumaran; Chris S Karapetis
Journal:  World J Oncol       Date:  2014-12-03

Review 9.  Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications.

Authors:  Feifei Teng; Min Li; Jinming Yu
Journal:  BMC Med       Date:  2020-09-18       Impact factor: 8.775

Review 10.  Imaging of acute and subacute toxicities of cancer therapy in children.

Authors:  Govind B Chavhan; Paul S Babyn; Paul C Nathan; Sue C Kaste
Journal:  Pediatr Radiol       Date:  2015-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.